← FDA DRUG APPROVALS

FDA ANDA · ANDA076212

CARBIDOPA AND LEVODOPA

Sponsor: APOTEX

APPLICATION
ANDA076212
TYPE
ANDA
ORIGINAL APPROVAL
2004-06-16
LATEST ACTION
2015-11-17
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

CARBIDOPA AND LEVODOPADiscontinued
CARBIDOPA 25MG, LEVODOPA 100MG · TABLET, EXTENDED RELEASE · ORAL
CARBIDOPA AND LEVODOPADiscontinued
CARBIDOPA 50MG, LEVODOPA 200MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2015-11-17Labeling · Supplement 11 · standardAP
2010-12-30Labeling · Supplement 9AP
2004-06-16OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →